RecruitingNCT07236203
Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
Sponsor
Fudan University
Enrollment
80 participants
Start Date
Feb 29, 2024
Study Type
OBSERVATIONAL
Summary
This is a single-center real-world study aiming to explore predictive factors for the efficacy of CAR-T therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Pathological diagnosis confirmed as large B-cell lymphoma
- Patients with relapsed or refractory large B-cell lymphoma (R/R DLBCL) after receiving second-line or above systemic treatment
- Intend to use CAR-T products approved by NMPA for the treatment of R/R LBCL.
- Understand and voluntarily sign a written informed consent form. For patients without full civil capacity, their guardians must be informed and sign the corresponding informed consent form and note the date, as for the patient himself, informed consent may be obtained based on the specific circumstances.
Exclusion Criteria3
- Poor patient compliance
- During pregnancy or lactation
- After judgment by the researcher, the patient has other unsuitable conditions for inclusion in the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGCAR-T
CD19 CAR-T
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07236203